Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - clindamycin hydrochloride, quantity: 177.515 mg (equivalent: clindamycin, qty 150 mg) - capsule, hard - excipient ingredients: titanium dioxide; purified talc; lactose monohydrate; magnesium stearate; gelatin; maize starch; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; industrial methylated spirit; iron oxide black; shellac; sulfuric acid; ammonia; dimeticone 1510; lecithin; ethanol; strong ammonia solution; potassium hydroxide - indications as at 20 june 2005 : dalacin c clindamycin is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. dalacin c clindamycin is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci and staphylococci. its use should be reserved for penicillin - allergic patients or other patients for whom, in the judgement of the physician, a penicillin is inappropriate. anaerobes - serious respiratory tract infections such as empyema, anaerobic pneumonitis and lung abscess; serious skin and skin structure infections; septicaemia; intra-abdominal infections such as peritonitis and intra-abdominal abscess (typically resulting from anaerobic organisms resident in the normal gastrointestinal tract); infections of the female pelvis and genital tract such as endometritis, non-gonococcal tubo-ovarian abscess, pelvic cellulitis and post-surgical vaginal cuff infection. streptococci - serious respiratory tract infections; serious ski

Israel - English - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - clindamycin phosphate - cream - clindamycin phosphate 2 %w/w - clindamycin - clindamycin - treatment of bacterial vaginosis only if bacteria susceptible to clindamycin were found.

Israel - English - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - clindamycin hydrochloride - capsules - clindamycin hydrochloride 150 mg - clindamycin - clindamycin - treatment of infections caused by susceptible strains of anaerobic microorganisms.

Israel - English - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - clindamycin hydrochloride - capsules - clindamycin hydrochloride 300 mg - clindamycin - clindamycin - treatment of infections caused by susceptible anaerobic bacteria.

Canada - English - Health Canada

bausch health, canada inc. - clindamycin (clindamycin phosphate) - solution - 1% - clindamycin (clindamycin phosphate) 1% - antibiotics

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - clindamycin -

Israel - English - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - clindamycin phosphate - solution for injection - clindamycin phosphate 150 mg/ml - clindamycin - clindamycin - for the treatment of infections caused by susceptible anaerobic bacteria.

Canada - English - Health Canada

pfizer canada ulc - clindamycin (clindamycin 2-palmitate hydrochloride) - granules for solution - 75mg - clindamycin (clindamycin 2-palmitate hydrochloride) 75mg - lincomycins

Ireland - English - HPRA (Health Products Regulatory Authority)

pfizer healthcare ireland - clindamycin - cutaneous emulsion - 10 milligram(s)/millilitre - antiinfectives for treatment of acne; clindamycin

Canada - English - Health Canada

taro pharmaceuticals inc - clindamycin (clindamycin phosphate) - solution - 1% - clindamycin (clindamycin phosphate) 1% - antibiotics